Pancreatic Cancer Research Reagents

Pancreatic ductal adenocarcinoma (PDAC) is characterized by near-universal KRAS mutations (~95%), extensive desmoplastic stroma, and profound immunosuppressive tumor microenvironment. Current treatment relies on FOLFIRINOX and nab-paclitaxel regimens, while emerging approaches include KRAS G12D-targeted therapies, stromal remodeling, and vaccine-based immunotherapy. Early detection remains a critical unmet need.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Pancreatic Cancer Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets in pancreatic cancer. KRAS oncogenic signaling, desmoplastic stroma (FAP+ CAFs), mesothelin immunotherapy targets, and CA19-9 biomarker. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key pancreatic cancer research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

KRAS (G12D/G12V/G12R) — KRAS mutations are present in approximately 95% of PDAC, with G12D being the most frequent. Anti-KRAS antibodies and mutation-specific reagents support oncogenic signaling research, KRAS-targeted therapeutic development, and downstream MAPK/PI3K pathway activation studies.
→ Browse KRAS antibodies & proteins

CA19-9 (Sialyl Lewis A) — CA19-9 is the standard serum biomarker for PDAC diagnosis, treatment monitoring, and recurrence surveillance. Anti-CA19-9 antibodies and calibrator proteins enable ELISA assay development, IHC validation, and research into improved early detection biomarker panels.
→ Browse CA19-9 antibodies & proteins

Mesothelin (MSLN) — Mesothelin is overexpressed in PDAC and serves as a target for emerging immunotherapies including CAR-T cells and ADCs. Anti-mesothelin antibodies support IHC expression profiling, serum SMRP measurement, and therapeutic antibody competition studies.
→ Browse Mesothelin antibodies & proteins

FAP (Fibroblast Activation Protein) — FAP is highly expressed on cancer-associated fibroblasts (CAFs) in the desmoplastic PDAC stroma. Anti-FAP antibodies enable tumor microenvironment characterization, CAF isolation by flow cytometry, and research into FAP-targeted radioligand therapy and bispecific antibody approaches.
→ Browse FAP antibodies & proteins

References

1. Rahib L, et al. Projecting cancer incidence and deaths to 2030. Cancer Res. 2014;74(11):2913-2921. DOI

2. Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825. DOI

3. Waddell N, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501. DOI

4. Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-1703. DOI

5. Ho WJ, et al. The tumour microenvironment in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17(8):487-505. DOI